Tokhir Dadaev

Tokhir Dadaev

Auto-generated profile, based on publicly available information

Tokhir Dadaev

The Institute of Cancer Research, London, UK

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
Elena CastroElena Castro
Elena Castro
CGChee Goh
Chee Goh
DODavid Olmos
David Olmos
ESEd Saunders
Ed Saunders
DLDaniel Leongamornlert
Daniel Leongamornlert
RERosalind Eeles
Rosalind Eeles
Purpose: To analyze the baseline clinicopathologic characteristics of prostate tumors with germline BRCA1 and BRCA2 (BRCA1/2) mutations and the prognostic value of those mutations on prostate cancer (PCa) outcomes. Patients and Methods: This study analyzed the tumor features and outcomes of 2,019 patients with PCa (18 BRCA1 carriers, 61 BRCA2 carriers, and 1,940 noncarriers). The Kaplan-Meier method and Cox regression analysis were used to evaluate the associations between BRCA1/2 status and other PCa prognostic factors with overall survival (OS), cause-specific OS (CSS), CSS in localized PCa (CSS_M0), metastasis-free survival (MFS), and CSS from metastasis (CSS_M1). Results: PCa with germline BRCA1/2 mutations were more frequently associated with Gleason ≥ 8 (P = .00003), T3/T4 stage (P = .003), nodal involvement (P = .00005), and metastases at diagnosis (P = .005) than PCa in noncarriers. CSS was significantly longer in noncarriers than in carriers (15.7 v 8.6 years, multivariable analyses [MVA] P = .015; hazard ratio [HR] = 1.8). For localized PCa, 5-year CSS and MFS were significantly higher in noncarriers (96% v 82%; MVA P = .01; HR = 2.6%; and 93% v 77%; MVA P = .009; HR = 2.7, respectively). Subgroup analyses confirmed the poor outcomes in BRCA2 patients, whereas the role of BRCA1 was not well defined due to the limited size and follow-up in this subgroup. Conclusion: Our results confirm that BRCA1/2 mutations confer a more aggressive PCa phenotype with a higher probability of nodal involvement and distant metastasis. BRCA mutations are associated with poor survival outcomes and this should be considered for tailoring clinical management of these patients.

27 March 2013 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TIThe COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative
The COGS–Cancer Research UK GWAS–ELLIPSE (part of GAME-ON) Initiative
RERosalind Eeles
Rosalind Eeles
TBThe Australian Prostate Cancer Bioresource
The Australian Prostate Cancer Bioresource
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
TCThe UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators
The UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators
DEDouglas F Easton
Douglas F Easton

4 January 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
DCDavid V. Conti
David V. Conti
BDBurcu F. Darst
Burcu F. Darst
LMLilit C. Moss
Lilit C. Moss
ESEdward J. Saunders
Edward J. Saunders
XSXin Sheng
Xin Sheng
CHChristopher A. Haiman
Christopher A. Haiman

14 September 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
AOAli Amin Al Olama
Ali Amin Al Olama
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
SBSonja I Berndt
Sonja I Berndt
DCDavid V Conti
David V Conti
FSFredrick Schumacher
Fredrick Schumacher
CHChristopher A Haiman
Christopher A Haiman
Rosalind Eeles, Christopher Haiman and colleagues report genome-wide association and meta-analyses of prostate cancer in populations of European, African, Japanese and Latino ancestry. They identify 23 new susceptibility loci, including one associated with early-onset prostate cancer. Genome-wide association studies (GWAS) have identified 76 variants associated with prostate cancer risk predominantly in populations of European ancestry. To identify additional susceptibility loci for this common cancer, we conducted a meta-analysis of >10 million SNPs in 43,303 prostate cancer cases and 43,737 controls from studies in populations of European, African, Japanese and Latino ancestry. Twenty-three new susceptibility loci were identified at association P < 5 × 10−8; 15 variants were identified among men of European ancestry, 7 were identified in multi-ancestry analyses and 1 was associated with early-onset prostate cancer. These 23 variants, in combination with known prostate cancer risk variants, explain 33% of the familial risk for this disease in European-ancestry populations. These findings provide new regions for investigation into the pathogenesis of prostate cancer and demonstrate the usefulness of combining ancestrally diverse populations to discover risk loci for disease.

27 September 2011 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
TCThe Ukgpcs Collaborators
The Ukgpcs Collaborators
ZKZ Kote-Jarai
Z Kote-Jarai
DLD Leongamornlert
D Leongamornlert
ESEd Saunders
Ed Saunders
MTM Tymrakiewicz
M Tymrakiewicz
RERosalind Eeles
Rosalind Eeles
Background: A family history of prostate cancer (PrCa) is a strong risk factor for the disease, indicating that inherited factors are important in this disease. We previously estimated that about 2% of PrCa cases diagnosed ⩽55 years harbour a BRCA2 mutation and PrCa among BRCA2 carriers has been shown to be more aggressive, with poorer survival. Methods: To further evaluate the role of BRCA2 in PrCa predisposition, we screened 1864 men with PrCa aged between 36 and 88 years. We analysed the BRCA2 gene using a novel high-throughput multiplex fluorescence heteroduplex detection system developed for the ABI3130xl genetic analyzer. Results: We identified 19 protein-truncating mutations, 3 in-frame deletions and 69 missense variants of uncertain significance (UV) in our sample set. All the carriers of truncating mutations developed PrCa at ⩽65 years, with a prevalence of BRCA2 mutation of 1.20% for cases in this age group. Conclusion: Based on the estimated frequency of BRCA2 mutations in the United Kingdom we estimate that germline mutations in the BRCA2 gene confer an ∼8.6-fold increased risk of PrCa by age 65, corresponding to an absolute risk of ∼15% by age 65. These results suggest that routine testing of early onset PrCa cases for germline BRCA2 mutations will further help to refine the prevalence and risk associated with BRCA2 mutations and may be useful for guiding management options.

10 July 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TOThe UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
The UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology
ZKZsofia Kote-Jarai
Zsofia Kote-Jarai
TCThe PRACTICAL Consortium
The PRACTICAL Consortium
AOAli Amin Al Olama
Ali Amin Al Olama
GGGraham G Giles
Graham G Giles
RERosalind Eeles
Rosalind Eeles